/

CSTL

Castle Biosciences, Inc.Open

32.91+0.15 +0.46%USD

NasdaqGM · as of Oct 13, 11:21 ET · 15m delay

Open

32.79

Prev close

32.76

Day range

32.2333.05

52-week range

17.7244.28

Volume

47.92K0.12×

Mkt cap

1.01B

P/E ttm

—

Fwd P/E

-35.05

EPS ttm

-0.6400

Div yield

0.00%

Earnings

Jul 30, 2026

From 52w high

−25.68%

Price Chart

Yahoo Finance · delayed

CSTLOct 13, 2026O 32.79H 33.04L 32.23C 32.91+0.15 (+0.46%)Vol 47.92K

SMA 5033.41
SMA 20028.87

1Y change +42.59% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

CSTL Castle Biosciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.35%
1 month: +1.79%
3 months: +42.34%
6 months: +35.04%
Year to date: −15.40%
1 year: +44.28%

Valuation & ownership

Market cap: 1.01B
Enterprise value: 770.65M
P/E (ttm): —
Forward P/E: -35.05
PEG ratio: —
Price / book: 2.14
Price / sales (ttm): 2.81
EV / EBITDA: -46.66
EPS (ttm): -0.6400
EPS (forward): -0.9389
Beta (5y monthly): 0.94
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 30.55M
Float: 27.16M
Short % of float: 6.70%
Short ratio (days): 5.82
Held by insiders: 2.40%
Held by institutions: 91.02%
Avg volume (3m): 403.07K
50-day average: 33.36
200-day average: 28.91
52-week change: +44.28%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 44.8
vs 50-day SMA: −1.49%
vs 200-day SMA: +13.98%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 4.99%
Realised vol (20d, ann.): 48.4%
From 52-week high: −25.68%
From 52-week low: +85.70%

ANR

Analyst Consensus

9 analysts

Consensus

Strong buy

1.00 on a 1 (strong buy) – 5 (sell) scale

Mean target

45.22

+37.41% implied

Low 35.00Median 45.00High 57.00

Recommendation trend

Now9 / 0 / 0
1m ago9 / 0 / 0
2m ago

DES

About Castle Biosciences, Inc.

Yahoo Finance profile

Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Sector: Healthcare
Industry: Diagnostics & Research
Employees: 1,002
Headquarters: Friendswood, TX, United States
Website: castlebiosciences.com
Officers: Mr. Derek J. Maetzold Founder, CEO, President & Director

SEAS

Seasonality · CSTL

2019–2026 · monthly returns

Strongest month Aug +24.78%Weakest month Sep −10.06%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	1.3	-24.9	-17.0	-0.2	-13.9	13.1	17.4	18.0	7.6	-7.4			−15.4%
2025	6.1	-23.3	-7.7	0.1	-20.3	27.9	-25.8	58.5	-5.2	12.0	56.7	-2.6	+46.0%
2024	7.0	-21.8	22.6	-4.8	10.3	-6.4	10.8	23.0	-3.9	21.6	-12.7	-12.0	+23.5%
2023	15.0	-7.0	-9.8	-0.4	8.0	-43.8	22.8	18.3	-15.3	-7.5	28.0	8.0	−8.3%
2022	0.9	0.1	3.6	-50.2	-0.3	-1.4	27.4	3.7	-10.1	-2.1	-7.6	-0.2	−45.1%
2021	-0.5	13.8	-10.0	0.8	-13.2	22.4	-4.7	9.8	-13.3	-6.2	-33.7	3.7	−36.2%
2020	-10.3	-2.9	-0.4	3.8	24.2	-1.9	2.7	18.1	12.5	-9.8	2.4	41.2	+95.4%
2019								42.1	-35.2	30.1	14.4	27.6	+74.9%

INSD

Insider Activity · CSTL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

221.1K shares

Sells, 6 months

322.6K shares

Net shares

−101.5K

Net change in insider shares

−12.20%

Date	Insider	Transaction	Shares	Value
Oct 4, 2026	Maetzold Derek JChief Executive Officer	Sale at price 35.57 per share.	14.5K	$515.57K
Oct 4, 2026	Maetzold Derek JChief Executive Officer	Conversion of Exercise of derivative security at price 2.39 per share.	8.2K	$19.51K
Sep 30, 2026	Oelschlager Kristen MChief Operating Officer	Sale at price 35.75 - 36.38 per share.	4.2K	$149.32K
Sep 30, 2026	Oelschlager Kristen MChief Operating Officer	Conversion of Exercise of derivative security at price 3.38 per share.	4.2K	$14.04K
Sep 29, 2026	Juvenal Tobin WOfficer	Sale at price 34.20 - 35.50 per share.	6.6K	$232.13K
Sep 20, 2026	Maetzold Derek JChief Executive Officer	Sale at price 35.33 per share.	14.5K	$512.20K
Sep 20, 2026	Maetzold Derek JChief Executive Officer	Conversion of Exercise of derivative security at price 2.39 per share.	8.6K	$20.51K
Sep 14, 2026	Juvenal Tobin WOfficer	Sale at price 32.32 - 35.14 per share.	6.6K	$222.62K
Sep 10, 2026	Maetzold Derek JChief Executive Officer	Sale at price 32.00 - 32.78 per share.	14.5K	$464.87K
Sep 10, 2026	Maetzold Derek JChief Executive Officer	Conversion of Exercise of derivative security at price 2.39 per share.	8.6K	$20.52K
Aug 31, 2026	Oelschlager Kristen MChief Operating Officer	Sale at price 33.36 - 34.02 per share.	4.2K	$138.64K
Aug 31, 2026	Oelschlager Kristen MChief Operating Officer	Conversion of Exercise of derivative security at price 3.38 per share.	4.2K	$14.03K
Aug 30, 2026	Juvenal Tobin WOfficer	Sale at price 32.81 per share.	1.7K	$56.76K
Aug 27, 2026	Maetzold Derek JChief Executive Officer	Sale at price 33.14 - 33.88 per share.	18.6K	$616.13K
Aug 27, 2026	Maetzold Derek JChief Executive Officer	Conversion of Exercise of derivative security at price 2.39 per share.	12.4K	$29.70K
Aug 24, 2026	Oelschlager Kristen MChief Operating Officer	Sale at price 33.69 - 34.64 per share.	24.6K	$837.87K
Aug 24, 2026	Juvenal Tobin WOfficer	Sale at price 35.04 per share.	9.1K	$317.11K
Aug 16, 2026	Juvenal Tobin WOfficer	Sale at price 29.59 per share.	1.7K	$51.19K
Aug 13, 2026	Stokes Franklin M.Chief Financial Officer	Sale at price 29.77 per share.	24.9K	$741.51K
Aug 13, 2026	Maetzold Derek JChief Executive Officer	Sale at price 30.02 per share.	7.2K	$217.10K

13F

Investors Holding CSTL

latest 13F filings of 29 followed managers

Investors holding CSTL
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$8.9M	0.01%	371.20K	−30%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

CSTL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

CSTL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Castle Biosciences, Inc.

Seasonality · CSTL

Insider Activity · CSTL

Congress Trades · CSTL

Investors Holding CSTL

Investors Holding CSTL

Congress Trades · CSTL

Insider Activity · CSTL

Seasonality · CSTL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Castle Biosciences, Inc.

Financial Snapshot

Earnings & Dividends

News